Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Information Services Group

Office Depot

Sprouts Farmers Markets

Top Ranked Growth Stocks to Buy for December 23rd

LabCorp (LH) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love LabCorp (LH)

DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Walgreens today announced that the Pixel by Labcorp™ At-Home COVID-19 Collection Kit is now available from Labcorp through Walgreens Find Care®, a digital health platform available on the Walgreens app and Walgreens.com. Walgreens currently offers COVID-19 testing in more than 1,100 drive-thru locations across

Walgreens and Labcorp Make Pixel by Labcorp™ At-Home COVID-19 Collection Kit Available Through Walgreens Find Care®

LH vs. XRAY: Which Stock Is the Better Value Option?

Boise Cascade

General Motors

Top Ranked Growth Stocks to Buy for December 15th

This approval is expected to increase access to LabCorp's (LH) COVID-19 testing, thereby broadening its customer base.

LabCorp's (LH) Pixel Kit Gets EUA for Over-the-Counter Use

LabCorp has now become the first company to receive approval to sell its COVID-19 test kit over-the-counter without a prescription, according to a statement form the company. One of the largest diagnostics testing companies in the U.S., LabCorp could be a significant competitor to companies like EverlyWell, which received approvals for its at-home testing kits […]

LabCorp COVID-19 test kit has just been approved for sale over-the-counter

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Pixel by LabCorp™ COVID-19 Test Home Collection Kit to become the first to be available over the counter without requiring a prescription. The kit is currently available through the Pixel by LabCorp website, and this a

LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail

Is Laboratory Corporation (LH) a great pick from the value investor's perspective right now? Read on to know more.

Is Laboratory Corporation (LH) a Good Stock to Pick Now?

Top Ranked Growth Stocks to Buy for December 9th

Abbott Labs

QuidelOrtho Corp

Quest Diagnostics

Our indicative theme of Covid-19 Testing Stocks- which includes the stocks of companies that produce or carry out tests for the highly infectious virus - is up by about 51% year-to-date, on an equally weighted basis, compared to the broader S&P 500 which is up around 15%. While the conversation.

Quidel, Abbott, Quest: Why Covid-19 Testing Stocks Are Still Worth A Look

In oncology too, LabCorp (LH) receives a significant award to be the partner of choice for late-stage oncology studies from a major pharmaceutical company.

LabCorp (LH) Covance Arms Shows Momentum Amid COVID-19 Woes

Hibbett Sports

Owens & Minor

Top Ranked Growth Stocks to Buy for December 7th

Landbridge Co LLC

Masco

TEGNA

Whirlpool

While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.

5 Top PEG-Focused Value Picks to Shield From External Shocks

LabCorp (LH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why LabCorp (LH) is a Solid Choice

IDEXX Laboratories

Thermo Fisher Scientific

To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.

3 Growth Stocks to Tap the COVID-Driven Shift in MedTech

MACOM Technology Solutions Holdings

Top Ranked Growth Stocks to Buy for December 3rd

LH vs. CNMD: Which Stock Is the Better Value Option?

LH or CNMD: Which Is the Better Value Stock Right Now?

Hologic

PerkinElmer

Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.

4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success

Top Ranked Growth Stocks to Buy for November 27th

TopBuild

Fair Isaac

After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.

5 Best Momentum Picks Using Driehaus Strategy

LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.

LabCorp (LH) Expands in New Jersey With Clinical Trial Deal

Top Ranked Growth Stocks to Buy for November 25th

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that members of the executive management team will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 3 at 1:50 p.m. ET. A live webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay. About LabCorp La

LabCorp Is Scheduled to Present at The 2020 Evercore ISI 3rd Annual HealthCONx Conference

Honda

Spectrum Brands Hlds

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects. Some such stocks are LH, ODP, HMC, SPB and BCC.

News for Labcorp Holdings Inc Stock (LH)